174 related articles for article (PubMed ID: 32553432)
1. A meta-analysis of craving studies in schizophrenia spectrum disorders.
Dondé C; Achim AM; Brunelin J; Poulet E; Mondino M; Haesebaert F
Schizophr Res; 2020 Aug; 222():49-57. PubMed ID: 32553432
[TBL] [Abstract][Full Text] [Related]
2. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis.
Potvin S; Joyal CC; Pelletier J; Stip E
Schizophr Res; 2008 Mar; 100(1-3):242-51. PubMed ID: 17614260
[TBL] [Abstract][Full Text] [Related]
3. The centrality of craving in network analysis of five substance use disorders.
Gauld C; Baillet E; Micoulaud-Franchi JA; Kervran C; Serre F; Auriacombe M
Drug Alcohol Depend; 2023 Apr; 245():109828. PubMed ID: 36868091
[TBL] [Abstract][Full Text] [Related]
4. Circadian functioning and quality of life in substance use disorder patients with and without comorbid schizophrenia.
Hashemzadeh I; Navarro JF; Adan A
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Jan; 120():110623. PubMed ID: 36029929
[TBL] [Abstract][Full Text] [Related]
5. Strategies to cope with treatment in substance use disorder male patients with and without schizophrenia.
Marquez-Arrico JE; Benaiges I; Adan A
Psychiatry Res; 2015 Aug; 228(3):752-9. PubMed ID: 26073284
[TBL] [Abstract][Full Text] [Related]
6. Item Response Theory analyses of DSM-5 substance use disorder criteria in French outpatient addiction clinic participants. How much is craving special?
Kervran C; Shmulewitz D; Serre F; Stohl M; Denis C; Hasin D; Auriacombe M
Drug Alcohol Depend; 2020 Jul; 212():108036. PubMed ID: 32464467
[TBL] [Abstract][Full Text] [Related]
7. Temperament and character dimensions in male patients with substance use disorders: Differences relating to psychiatric comorbidity.
Marquez-Arrico JE; López-Vera S; Prat G; Adan A
Psychiatry Res; 2016 Mar; 237():1-8. PubMed ID: 26921044
[TBL] [Abstract][Full Text] [Related]
8. Validity of the DSM-5 craving criterion for alcohol, tobacco, cannabis, cocaine, heroin, and non-prescription use of prescription painkillers (opioids).
Shmulewitz D; Stohl M; Greenstein E; Roncone S; Walsh C; Aharonovich E; Wall MM; Hasin DS
Psychol Med; 2023 Apr; 53(5):1955-1969. PubMed ID: 35506791
[TBL] [Abstract][Full Text] [Related]
9. Circadian rhythmicity in schizophrenia male patients with and without substance use disorder comorbidity.
Adan A; Marquez-Arrico JE; Río-Martínez L; Navarro JF; Martinez-Nicolas A
Eur Arch Psychiatry Clin Neurosci; 2024 Mar; 274(2):279-290. PubMed ID: 36879135
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Course of Clients With Co-occurring Schizophrenia-Spectrum and Substance Use Disorders in Urban Mental Health Centers: A 7-Year Prospective Study.
Drake RE; Luciano AE; Mueser KT; Covell NH; Essock SM; Xie H; McHugo GJ
Schizophr Bull; 2016 Jan; 42(1):202-11. PubMed ID: 26294706
[TBL] [Abstract][Full Text] [Related]
11. Morbidity and mortality in schizophrenia with comorbid substance use disorders.
Lähteenvuo M; Batalla A; Luykx JJ; Mittendorfer-Rutz E; Tanskanen A; Tiihonen J; Taipale H
Acta Psychiatr Scand; 2021 Jul; 144(1):42-49. PubMed ID: 33650123
[TBL] [Abstract][Full Text] [Related]
12. Patients with Schizophrenia Showed Worse Cognitive Performance than Bipolar and Major Depressive Disorder in a Sample with Comorbid Substance Use Disorders.
Marquez-Arrico JE; Gonzalez-Sanchez A; Navarro JF; Penadés R; Adan A
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431125
[TBL] [Abstract][Full Text] [Related]
13. Comorbid substance-use in schizophrenia: relation to positive and negative symptoms.
Talamo A; Centorrino F; Tondo L; Dimitri A; Hennen J; Baldessarini RJ
Schizophr Res; 2006 Sep; 86(1-3):251-5. PubMed ID: 16750347
[TBL] [Abstract][Full Text] [Related]
14. Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine.
Mesholam-Gately RI; Gibson LE; Seidman LJ; Green AI
Schizophr Res; 2014 May; 155(1-3):45-51. PubMed ID: 24685823
[TBL] [Abstract][Full Text] [Related]
15. Temperament and Character Profile and Its Clinical Correlates in Male Patients with Dual Schizophrenia.
Río-Martínez L; Marquez-Arrico JE; Prat G; Adan A
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32560099
[TBL] [Abstract][Full Text] [Related]
16. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.
Wobrock T; Falkai P; Schneider-Axmann T; Hasan A; Galderisi S; Davidson M; Kahn RS; Derks EM; Boter H; Rybakowski JK; Libiger J; Dollfus S; López-Ibor JJ; Peuskens J; Hranov LG; Gaebel W; Fleischhacker WW;
Schizophr Res; 2013 Jun; 147(1):132-139. PubMed ID: 23537477
[TBL] [Abstract][Full Text] [Related]
17. Violent persons with schizophrenia and comorbid disorders: a functional magnetic resonance imaging study.
Joyal CC; Putkonen A; Mancini-Marïe A; Hodgins S; Kononen M; Boulay L; Pihlajamaki M; Soininen H; Stip E; Tiihonen J; Aronen HJ
Schizophr Res; 2007 Mar; 91(1-3):97-102. PubMed ID: 17291724
[TBL] [Abstract][Full Text] [Related]
18. Addictive behaviors and craving during the COVID-19 pandemic of people who have recovered from substance use disorder.
Bonny-Noach H; Gold D
J Addict Dis; 2021; 39(2):257-264. PubMed ID: 33305702
[TBL] [Abstract][Full Text] [Related]
19. Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders.
Icick R; Moggi F; Slobodin O; Dom G; Mathys F; van den Brink W; Levin FR; Blankers M; Kaye S; Demetrovics Z; van de Glind G; Velez-Pastrana MC; Schellekens ASA;
Eur Addict Res; 2020; 26(4-5):201-210. PubMed ID: 32570249
[TBL] [Abstract][Full Text] [Related]
20. Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study.
Lombardozzi G; Trovini G; Amici E; Kotzalidis GD; Perrini F; Giovanetti V; Di Giovanni A; De Filippis S
Front Psychiatry; 2023; 14():1321233. PubMed ID: 38111619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
